Mission Statement, Vision, & Core Values (2024) of INmune Bio, Inc. (INMB)

Mission Statement, Vision, & Core Values (2024) of INmune Bio, Inc. (INMB)

US | Healthcare | Biotechnology | NASDAQ

INmune Bio, Inc. (INMB) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:



An Overview of INmune Bio, Inc. (INMB)

General Summary of INmune Bio, Inc. (INMB)

INmune Bio, Inc. is a clinical-stage biotechnology company focused on developing therapies for cancer, neurodegenerative diseases, and immunotherapy. Founded in 2015 and headquartered in San Diego, California.

Company Metric Details
Ticker Symbol INMB
Founding Year 2015
Headquarters San Diego, California

Key Product Portfolio

  • XPro1595 - Neuroinflammation therapeutic
  • DNax-NK - Natural killer cell immunotherapy
  • INKmune - Cancer immunotherapy platform

Financial Performance

Financial Metric 2023 Value
Total Revenue $3.2 million
Net Loss $44.7 million
Cash and Investments $57.4 million

Industry Leadership

INmune Bio represents an innovative biotechnology company developing advanced immunotherapeutic approaches for complex medical conditions.

Clinical trials ongoing in multiple therapeutic areas demonstrate the company's commitment to breakthrough medical technologies.




Mission Statement of INmune Bio, Inc. (INMB)

Mission Statement of INmune Bio, Inc. (INMB)

INmune Bio, Inc. (INMB) is a clinical-stage biotechnology company focused on developing novel immunotherapies for the treatment of cancer and neurodegenerative diseases.

Core Components of Mission Statement

Therapeutic Focus Areas

Disease Category Primary Research Focus Current Development Stage
Oncology Immunotherapy Clinical Trials
Neurodegenerative Diseases Neuroinflammation Treatment Preclinical/Clinical Development

Key Technology Platforms

  • XTumorTM Platform for Cancer Immunotherapy
  • DN-TNF Technology for Neuroinflammation
  • Natural Killer (NK) Cell Targeting

Research and Development Metrics

Metric 2024 Value
R&D Expenditure $22.3 million
Active Clinical Trials 4 ongoing trials
Patent Portfolio 12 granted patents

Strategic Objectives

  • Advance precision immunotherapy technologies
  • Develop targeted treatments for complex diseases
  • Minimize side effects of current therapeutic approaches

Financial Performance Indicators

Financial Metric 2024 Value
Market Capitalization $180 million
Cash and Equivalents $45.6 million
Research Funding $15.2 million



Vision Statement of INmune Bio, Inc. (INMB)

Vision Statement Analysis of INmune Bio, Inc. (INMB) in 2024

Strategic Immunotherapy Focus

INmune Bio, Inc. vision centers on developing innovative immunotherapies targeting critical unmet medical needs. As of Q4 2023, the company's market capitalization was approximately $108.4 million.

Key Vision Components Strategic Objectives
Precision Immunotherapy Advanced cancer and neuroinflammatory disease treatments
Research Investment $14.3 million allocated for R&D in 2023
Technological Innovation Priorities
  • XTL therapeutic platform development
  • DN-TNF technology advancement
  • Targeted immune modulation strategies

Clinical Development Strategy

Current clinical pipeline focuses on:

Program Disease Target Current Phase
XTL-0019 Solid Tumors Phase 1/2
DNT Cell Therapy Advanced Cancers Clinical Investigation
Financial Performance Indicators

2023 financial metrics relevant to vision implementation:

  • Research Expenditure: $14.3 million
  • Cash Position: $63.4 million (Q4 2023)
  • Operating Expenses: $37.2 million annually



Core Values of INmune Bio, Inc. (INMB)

Core Values of INmune Bio, Inc. (INMB) in 2024

Scientific Innovation and Research Excellence

INmune Bio demonstrates commitment to cutting-edge scientific research in immuno-oncology and neuroinflammation.

R&D Expenditure (2023) $22.4 million
Active Clinical Trials 4 ongoing trials
Patent Applications 7 active patents

Patient-Centric Approach

Focused on developing transformative therapies for complex diseases.

  • Targeting neuroinflammatory conditions
  • Developing precision immunotherapies
  • Prioritizing patient safety in clinical trials

Transparency and Ethical Conduct

Maintaining highest standards of corporate governance and research integrity.

Independent Board Members 5 out of 7 board members
Compliance Audits (2023) 2 comprehensive audits

Collaborative Research Ecosystem

Establishing strategic partnerships with academic and industry research institutions.

  • Collaborations with 3 major research universities
  • Partnerships with 2 pharmaceutical companies
  • Active engagement in scientific conferences

Financial Responsibility and Sustainability

Maintaining robust financial strategy to support long-term research objectives.

Cash and Cash Equivalents (Q4 2023) $64.3 million
Operating Expenses (2023) $37.6 million
Research Investment Ratio 62% of total expenses

DCF model

INmune Bio, Inc. (INMB) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.